|1.||Goshima, Yoshio: 13 articles (09/2015 - 06/2006)|
|2.||Lennon, Vanda A: 8 articles (07/2014 - 07/2003)|
|3.||Nagashima, Yoji: 7 articles (11/2014 - 12/2008)|
|4.||Vadasz, Zahava: 6 articles (10/2015 - 01/2012)|
|5.||Jayakumar, Calpurnia: 6 articles (06/2015 - 01/2013)|
|6.||Ramesh, Ganesan: 6 articles (06/2015 - 01/2013)|
|7.||Nakamura, Fumio: 6 articles (11/2014 - 12/2008)|
|8.||Pittock, Sean J: 6 articles (07/2014 - 07/2005)|
|9.||Taniguchi, Masahiko: 6 articles (07/2014 - 02/2002)|
|10.||Haj, Tharwat: 5 articles (10/2015 - 01/2012)|
01/01/2012 - "Current studies have shown that axonal sprouting inhibitor, semaphorin 3A (Sema 3A) acts as a potent suppressor of tumor angiogenesis in various cancer models. "
12/01/2007 - "Thus, this study is the first to quantify expression of the SEMA3A system in human malignancy and to show that overexpression of SEMA3A by nerves and transformed cells leads to a SEMA3A-rich environment which may favor malignant activities of tumor cells. "
10/30/2014 - "High mobility group box 1 promotes tumor cell migration through epigenetic silencing of semaphorin 3A."
01/01/2014 - "SEMA3A has been shown to be a tumor suppressor in various cancers. "
12/09/2013 - "Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity."
|2.||Wounds and Injuries (Trauma)
06/10/2012 - "Phosphorylation and cleavage of the family of collapsin response mediator proteins may play a central role in neurodegeneration after CNS trauma."
10/31/2003 - "SM-216289 is an excellent molecular probe to investigate the function of Sema3A, in vitro and in vivo, and may be useful for the treatment of traumatic neural injuries."
10/01/2012 - "The study also revealed that Sema3A expression is up-regulated in primary satellite-cell cultures in response to hepatocyte growth factor (HGF) and basic fibroblast growth factor (FGF2) and is prevented by transforming growth factor (TGF)-β2, 3. In order to verify the physiological significance of this regulation in vitro, the present study was designed to estimate the time-course of extracellular HGF, FGF2 and TGF-β3 concentrations after crush-injury of Gastrocnemius muscle in the rat lower hind-limb, using a combination of a non-homogenization/non-spin extraction of extracellular wound fluids and enhanced chemiluminescence-Western blotting analyses. "
07/15/2014 - "Genetic inactivation of sema3A protected mice from ischemia-reperfusion-induced AKI, improved tissue histology, reduced neutrophil infiltration, prevented epithelial cell apoptosis, and increased cytokine and chemokine excretion in urine. "
07/15/2014 - "Pharmacological-based inhibition of sema3A receptor binding likewise protected against ischemia-reperfusion-induced AKI. "
07/01/2015 - "To investigate the activity of collapsin response mediator protein 2 (CRMP-2) and its possible regulation for axonal and dendrictic injury under hypoxia-ischemia (HI). "
07/15/2014 - "Semaphorin 3A inactivation suppresses ischemia-reperfusion-induced inflammation and acute kidney injury."
02/01/2013 - "Following middle cerebral artery occlusion to induce stroke in mice, immunohistochemistry shows both Sema3A and 12/15-LOX are increased in the cortex up to 2 wk. To determine whether a Sema3A-dependent damage pathway is activated following ischemia, we injected recombinant Sema3A into the striatum. "
12/01/2014 - "Increased semaphorin 3A was associated with severity of albuminuria. "
12/01/2014 - "Consistent with the mouse data, increased sema3A urinary excretion was detected in diabetic patients with albuminuria, particularly in those with macroalbuminuria. "
12/01/2009 - "Sema3a deletion resulted in defects in renal vascular patterning, excess endothelial cells within glomerular capillaries, effaced podocytes with extremely wide foot processes and albuminuria. "
05/01/2015 - "Moreover, sema3a binding inhibition or podocyte-specific plexinA1 deletion markedly ameliorates albuminuria and abrogates renal insufficiency and the diabetic nodular glomerulosclerosis phenotype of diabetic Sema3a(+) mice. "
12/01/2014 - "Genetic ablation of sema3A or pharmacological inhibition with a novel sema3A inhibitory peptide was protected against diabetes-induced albuminuria, kidney fibrosis, inflammation, oxidative stress, and renal dysfunction. "
|5.||Neurologic Manifestations (Neurological Manifestations)
03/01/2008 - "In the 27 rigorously reported cases, neurologic manifestations other than visual loss have been present in all but 2. In the single case in which vision improved in response to treatment of the cancer, the collapsin response-mediating protein (CRMP)-5 titer did not change, and the ophthalmic examination was not detailed. "
07/01/2005 - "Coexisting paraneoplastic autoantibodies, identified in 74% of patients, predicted a common neoplasm and indicated other neuronal autoantigen targets that plausibly explained several neurological manifestations; for example, P/Q-type Ca(2+)-channel antibody with Lambert-Eaton syndrome (n = 5), anti-neuronal nuclear antibody type 1 with sensory neuronopathy (n = 7), K(+)-channel antibody with limbic encephalitis (n = 1) or neuromyotonia (n = 1), and collapsin response-mediator protein-5-IgG with optic neuritis (n = 3). "
|2.||glucuronyl glucosamine glycan sulfate (Vessel)
|4.||Molecular Probes (Molecular Probe)
|3.||Transplantation (Transplant Recipients)
|5.||Prostatectomy (Retropubic Prostatectomy)